title: Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.
abstract: OBJECTIVE
  Administration of chemotherapy in patients with renal failure, treated with hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) is still a challenge and literature data is scarce. Here we present a case study of a patient on CAPD, treated with weekly and three-weekly paclitaxel/carboplatin for recurrent ovarian cancer.
  
  
  METHODS
  During the first, second and ninth cycle of treatment, blood, urine and CAPD samples were collected for pharmacokinetic analysis of paclitaxel and total and unbound carboplatin-derived platinum.
  
  
  RESULTS
  Treatment was well tolerated by the patient. No excessive toxicity was observed and at the end of treatment she was in a complete remission. The plasma pharmacokinetics of paclitaxel were unaltered compared to historical data, with neglectable urinary and CAPD clearance. In contrast, the pharmacokinetics of carboplatin were altered, with doubled half-lives compared to patients with normal renal function. Of the administered carboplatin dose, up to 20% was cleared via the dialysate, while only up to 8% was cleared via the urine.
  
  
  CONCLUSIONS
  Paclitaxel and carboplatin can be safely administered to patients with chronic renal failure on CAPD. For paclitaxel the generally applied dose can be administered, and although for carboplatin dose-adjustment is required due to the diminished renal function, the dose can be calculated using Calvert's formula.
authors.affiliation: Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, University Medical Center, Room AS-15, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands.
authors.forename: Joan B
authors.initials: JB
authors.lastname: Heijns
authors.forename: Maria E L
authors.initials: ME
authors.lastname: van der Burg
authors.forename: Teun
authors.initials: T
authors.lastname: van Gelder
authors.forename: Marien W J A
authors.initials: MW
authors.lastname: Fieren
authors.forename: Peter
authors.initials: P
authors.lastname: de Bruijn
authors.forename: Ate
authors.initials: A
authors.lastname: van der Gaast
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Loos
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010531:Peritoneal Dialysis, Continuous Ambulatory; D051437:Renal Insufficiency / Q000150:complications / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel